The FDA unveiled draft guidance encouraging the validation of new approach methodologies (NAMs) that can reduce reliance on animal pharmacology and toxicology studies, signaling a shift toward more human‑centric preclinical pathways. Separately, the agency said it will consider Regenerative Medicine Advanced Therapy (RMAT) designations for programs that are on clinical hold, easing a procedural barrier for developers of cell and gene therapies. Together these actions reflect regulatory recalibration: the draft guidance aims to speed early development while maintaining safety through validated alternatives, and RMAT flexibility could keep promising regenerative programs eligible for expedited pathways despite temporary trial interruptions. Industry reactions ranged from cautious optimism to calls for clarity on qualification standards and evidentiary thresholds.